Jade Biosciences Announces Proposed Underwritten Public Offering

Jade Biosciences (Nasdaq: JBIO) plans a proposed underwritten public offering of common stock and, for certain investors, pre-funded warrants to buy common shares.

Rhea-AI Summary

Jade Biosciences (Nasdaq: JBIO) plans a proposed underwritten public offering of common stock and, for certain investors, pre-funded warrants to buy common shares. All securities will be sold by Jade, with underwriters receiving a 30-day option for up to 15% additional securities. Proceeds are intended to fund clinical trials, preclinical studies, manufacturing, R&D, capital spending, working capital and general corporate purposes.

Positive

• Proposed equity financing to support clinical, preclinical and manufacturing programs
• Existing shelf registration on Form S-3 effective May 15, 2026 facilitates offering access

Negative

• New shares and pre-funded warrants would increase share count if the offering is completed

Argus Jun 4 session

+0.85% close to close Open Argus

Details

News Market Reaction – JBIO

In the Jun 4 session, JBIO gained 0.85%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details Jade’s plan for an underwritten public offering of common stock and pre-fu...

Analysis

This announcement details Jade’s plan for an underwritten public offering of common stock and pre-funded warrants, with an additional 15% option for underwriters. It follows the establishment of an effective Form S-3 shelf and an unused $200.0 million ATM program, alongside previously disclosed liquidity of $311.3 million. Investors may focus on finalized deal terms, the balance between primary and resale capacity, and how proceeds support ongoing Phase 1 and Phase 2 programs.

Key Figures

Resale registration shares: 39,542,339 shares Primary shelf capacity: $600,000,000 ATM program size: $200,000,000 +5 more

Resale registration shares

39,542,339 shares

Shares of common stock registered for resale under S-3 shelf

Primary shelf capacity

$600,000,000

Maximum aggregate offering under Form S-3 shelf filed May 7, 2026

ATM program size

$200,000,000

At-the-market sales agreement capacity under May 7, 2026 shelf

Cash & investments

$311.3 million

Total liquidity as of March 31, 2026 from 10-Q

Net loss

$40.4 million

Net loss for quarter ended March 31, 2026

Operating cash outflow

$24.1 million

Cash used in operations in Q1 2026

Shares outstanding

49,345,967 shares

Common shares outstanding as of March 31, 2026 (S-3 shelf)

Shelf last sale price

$25.26 per share

Last reported Nasdaq sale price on May 5, 2026 in S-3

Historical Context

5 past events · Latest: Jun 01

5 events

1. Jun 01

   Phase 1 interim data

   24h Move

   -11.6%

   Positive interim Phase 1 JADE101 data with ~70% IgA reduction at 12 weeks.

2. May 29

   Data call announcement

   24h Move

   -11.6%

   Announcement of webcast to discuss interim Phase 1 JADE101 results.

3. May 26

   First-in-human start

   24h Move

   -1.0%

   First participant dosed in Phase 1 trial of JADE201 for autoimmune diseases.

4. May 26

   Phase 2 trial start

   24h Move

   -2.3%

   First participant dosed in JUNIPER Phase 2 trial of JADE101 in IgA nephropathy.

5. May 07

   Q1 2026 earnings

   24h Move

   +6.6%

   Q1 2026 results with $311.3M liquidity and detailed development milestones.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, pre-funded warrants, book-running managers, shelf registration statement, +2 more

6 terms

underwritten public offering financial

"it intends to offer and sell... in a proposed underwritten public offering."

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

book-running managers financial

"Jefferies, TD Cowen and UBS Investment Bank are acting as joint book-running managers"

Book-running managers are the main banks or financial firms that organize and oversee a company's sale of new stocks or bonds. They help set the price, decide how many to sell, and coordinate the process to make sure everything runs smoothly. Their role is important because they guide the company through the complex process of raising money from investors.

shelf registration statement regulatory

"The securities described above are being offered by Jade pursuant to a shelf registration statement"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3, including a base prospectus, that was previously filed"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in a proposed underwritten public offering. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering are being offered by Jade. In addition, Jade intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the securities offered in the public offering, at the public offering price, less underwriting discounts and commissions. There can be no assurance as to whether or when the proposed public offering may be completed, or as to the actual size or terms of the proposed offering.

Jade intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents, and investments, to fund clinical trials, preclinical studies, and manufacturing in support of its programs, as well as for additional research and development activities, capital expenditures, working capital and other general corporate purposes.

Jefferies, TD Cowen and UBS Investment Bank are acting as joint book-running managers for the proposed offering. LifeSci Capital is also acting as a book-running manager for the proposed offering. BTIG is acting as a lead manager for the proposed offering.

The securities described above are being offered by Jade pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (“SEC”) and was declared effective on May 15, 2026. A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. Copies of the prospectus supplement for this offering may be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; and UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, NY 10010, or by email at ol-prospectus-request@ubs.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Jade Biosciences, Inc.

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an undisclosed antibody program. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Forward Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, our expectations regarding the completion, timing, structure and size of the proposed offering and our intended use of net proceeds therefrom, and the grant of the option to purchase additional shares. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and its subsequent filings). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.

Jade Biosciences Contact

Priyanka Shah
Media@JadeBiosciences.com
IR@JadeBiosciences.com
908-447-6134

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jade Biosciences (NASDAQ: JBIO) announce on June 3, 2026?

Jade Biosciences announced a proposed underwritten public offering of common stock and pre-funded warrants. According to Jade, all securities will be sold by the company, with underwriters offered a 30-day option for up to 15% additional securities.

How large is the proposed Jade Biosciences (JBIO) stock offering?

The exact size of the Jade Biosciences proposed offering has not been disclosed. According to Jade, the deal’s completion, actual size and final terms remain subject to market conditions and may not occur as currently planned or at all.

What will Jade Biosciences use the JBIO offering proceeds for?

Jade Biosciences plans to use net proceeds to fund clinical trials, preclinical studies and manufacturing. According to Jade, remaining funds will support additional research and development, capital expenditures, working capital and other general corporate purposes alongside existing cash and investments.

What types of securities are included in the Jade Biosciences (JBIO) offering?

The offering includes shares of common stock and, for certain investors, pre-funded warrants to purchase common shares. According to Jade, all offered common stock and pre-funded warrants will be sold by the company under an underwritten public offering structure.

What is the 30-day underwriter option in the Jade Biosciences JBIO deal?

Underwriters may receive a 30-day option to buy up to 15% additional securities at the public offering price. According to Jade, this option covers the same securities offered and is subject to underwriting discounts and commissions.

Which banks are managing the Jade Biosciences (JBIO) proposed offering?

Jefferies, TD Cowen and UBS Investment Bank are joint book-running managers, with LifeSci Capital also a book-runner. According to Jade, BTIG will act as lead manager, coordinating alongside the primary underwriting banks on the proposed public offering.